MaxiVAX
Geneva
About MaxiVAX
MaxiVAX is a Swiss clinical-stage biotechnology company, currently performing a first-in-man (phase I) trial in various tumours with MVX-ONCO-1. MaxiVAX’ mission is to develop alternative solutions to “established cancer therapies” that are more effective, are personalized and enable the patient to fight his own disease. MaxiVAX’ first treatment, MVX-ONCO-1 has been classified as an Advanced Therapeutic Product by the European Medicines Agency. The resulting approval procedure is different than that of a traditional drug and should generally allow a faster development until market approval with fewer and less extensive clinical trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $8.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2019)
- Website: maxivax.ch
- Phone: +41 22 552 26 13
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/maxivax-78098 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.